L-Carnosine
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| CAS Number | 305-84-0 (verified against PubChem CID 439224) |
| Molecular Formula / MW | C9H14N4O3 / 226.23 g/mol |
| Chemical Class | Dipeptide — β-alanyl-L-histidine. Note the unusual β-amino acid |
| Source | Endogenous, at millimolar concentration in skeletal muscle, brain, and the lens of the eye; commercial material synthetic |
| Critical pharmacokinetic fact | Rapidly hydrolysed by serum carnosinase (CN1); plasma half-life ~1.2 minutes |
| Typical Standardisation | L-Carnosine by HPLC; ≥98–99% commercial grade |
| Claim Strength (Overview) | High for mechanism (anti-glycation, carbonyl scavenging, buffering); Emerging for oral supplementation, because of the carnosinase problem |
| Buy from Herbuno | L Carnosine Powder → |
Name origin: Carnosine derives from the Latin carnis (flesh), reflecting its discovery in muscle tissue by Gulewitsch in 1900. It is a dipeptide of β-alanine and L-histidine — and note the β: the alanine is joined through its beta carbon, an unusual linkage that is part of why carnosine resists ordinary peptidases while remaining vulnerable to one highly specific enzyme. Traditional use: None applies. Carnosine is an endogenous metabolite present at millimolar concentration in skeletal muscle, brain, and the lens of the eye, discovered in 1900 and characterised through the 20th century. It is abundant in meat — which is the only "traditional" route of intake. Research trajectory: Carnosine has an unusually rich and well-mapped mechanistic literature: it is a potent antioxidant scavenging oxygen free radicals and transition metal ions, blocks protein-protein and protein-DNA cross-links induced by hypochlorite and toxic aldehydes (acetaldehyde, formaldehyde, malondialdehyde), inhibits non-enzymatic protein glycation, and inhibits formation of advanced glycation end products. It is also a pH buffer in muscle. The mechanism is excellent. The problem: Humans, unlike most mammals, express high levels of serum carnosinase, which hydrolyses circulating carnosine within minutes. This single pharmacokinetic fact governs everything about oral carnosine, and it is the reason this page is more sceptical than the mechanism alone would warrant.
Evidence for L-Carnosine Applications
The carnosinase problem must be stated first, because it determines how every other claim on this page should be read. In humans, after oral consumption and absorption into circulation, carnosine is rapidly hydrolysed by serum carnosinase (CN1), resulting in a plasma half-life of approximately 1.20 ± 0.36 minutes — after which the dipeptide is not detectable in serum (Wheat 2024). A plasma half-life of roughly seventy seconds is not a footnote — it is a fundamental obstacle to any claim premised on carnosine circulating and acting systemically. Humans express serum carnosinase at levels most mammals do not, which is why rodent carnosine data translates poorly. Claim strength: High (established, and adverse to the supplement thesis).
The picture is not entirely bleak, and the redeeming findings are mechanistically specific. Erythrocytes appear to constitute a protective compartment: work using LC-MS found uptake of carnosine into human erythrocytes cultivated in the presence of the dipeptide and human serum, with protection from carnosinase degradation and no negative effect on ATP production (Oppermann 2021). Separately, some ingested carnosine localises in skeletal muscle, with studies showing skeletal muscle carnosine levels doubling in humans receiving supplements, and intact carnosine is excreted in urine for up to five hours after intake — which itself implies a protected compartment. Claim strength: Moderate.
The genetics point is the most interesting thing on this page and has real implications. A trinucleotide repeat polymorphism in CNDP1 (the gene encoding carnosinase) determines serum carnosinase activity, and individuals homozygous for the "Mannheim" allele have lower plasma carnosinase activity, higher plasma carnosine, and a reduced risk of diabetic nephropathy. In other words: the people who naturally degrade carnosine more slowly get a health benefit. This is a strong argument that carnosine matters — and simultaneously an argument that supplementing it may work poorly in the majority who degrade it fast. Both readings are honest. Claim strength: Moderate.
The anti-glycation mechanism is genuinely well characterised and is the compound’s best scientific claim. Carnosine inhibits non-enzymatic protein glycation induced by aldose and ketose reducing sugars, inhibits formation of toxic advanced glycation end products (AGEs), and acts as a nucleophilic carbonyl scavenger — sacrificially reacting with reactive carbonyl species such as malondialdehyde and methylglyoxal before they can damage proteins. This is a specific, mechanistically coherent activity, and it is the basis of the diabetic-complications research programme. Whether oral supplementation delivers it in humans is the open question. Claim strength: High (mechanism); Emerging (oral delivery).
The pragmatic alternative that formulators should know about: β-alanine. Because muscle carnosine synthesis is rate-limited by β-alanine availability, β-alanine supplementation is the established and well-evidenced route to raising muscle carnosine — and it sidesteps the carnosinase problem entirely, since β-alanine is not a carnosinase substrate. For any muscle-buffering or exercise-performance application, β-alanine has the stronger evidence and the better pharmacokinetic logic. A supplier who does not tell a customer this is not being straight with them. Claim strength: Moderate.
Dosage & Formulator Specification
Herbuno carries L-Carnosine Powder. Buyers should be aware that for muscle carnosine loading specifically, β-alanine is the better-evidenced and more pharmacokinetically sensible route, since it bypasses serum carnosinase entirely. L-carnosine itself is appropriate where the intact dipeptide is required — research applications, topical and ophthalmic formulation, and formulations targeting the erythrocyte or gut compartments.
Oral carnosine trial dosing has commonly used 1–2 g/day, with the diabetic nephropathy work using 2 g/day. The pharmacokinetic reality should be stated plainly rather than obscured: at a plasma half-life of roughly 1.2 minutes, escalating the oral dose does not straightforwardly produce proportional systemic exposure, because the rate-limiting step is enzymatic degradation rather than absorption. Formulators should scope claims to the compartments where carnosine demonstrably accumulates — skeletal muscle, erythrocytes — or to local applications, rather than to a systemic plasma-carnosine thesis the data does not support.
Analytical verification should specify L-carnosine by HPLC (≥98–99%) against a certified reference standard, with confirmation of the L-histidine stereochemistry — the D-isomer and racemic material are distinct products and are not physiologically equivalent. Related substances (free β-alanine, free histidine, anserine) should be quantified, since these are the natural degradation and synthesis-route impurities. Carnosine is hygroscopic; storage moisture control and packaging should be documented, along with residual solvent testing appropriate to the synthetic route.
L-Carnosine is an endogenous human metabolite present at millimolar concentration in muscle and abundant in dietary meat, and is well tolerated at supplement intakes; adverse effects are minimal and typically limited to mild gastrointestinal complaints. The principal thing a supplier owes a buyer here is not a safety warning but a pharmacokinetic one: human serum carnosinase hydrolyses circulating carnosine within about a minute, and this is the single most important fact about the ingredient. Any product positioned on systemic plasma carnosine elevation is positioned against the pharmacokinetics. Note also that carnosine may lower blood glucose, warranting the usual caution alongside antidiabetic medication, and that individuals with histidinaemia or on histidine-restricted diets should exercise care.
Frequently Asked Questions — L-Carnosine
Why is serum carnosinase such a problem?
Because it destroys the ingredient almost immediately. In humans, orally absorbed carnosine is hydrolysed by serum carnosinase (CN1) with a plasma half-life of about 1.2 minutes — roughly seventy seconds — after which it is undetectable in serum. Humans express this enzyme at levels most mammals do not, which is why rodent carnosine data translates poorly.
Then does oral carnosine do anything at all?
Some things, in specific compartments. Erythrocytes take up carnosine and protect it from carnosinase degradation. Skeletal muscle carnosine has been shown to double in humans receiving supplements. Intact carnosine appears in urine for up to five hours. So it is not useless — but a systemic plasma-carnosine thesis is not supported.
Should I use beta-alanine instead?
For muscle carnosine loading, almost certainly yes, and a supplier who does not tell you this is not being straight. Muscle carnosine synthesis is rate-limited by beta-alanine availability, and beta-alanine is not a carnosinase substrate — so it sidesteps the whole problem. It has both the stronger evidence and the better pharmacokinetic logic.
What is the genetic angle?
It is the most interesting thing about this compound. A CNDP1 repeat polymorphism determines carnosinase activity, and people homozygous for the "Mannheim" allele degrade carnosine more slowly, have higher plasma carnosine, and show reduced risk of diabetic nephropathy. That argues carnosine matters — and simultaneously that supplementing it may work poorly in the fast-degrading majority.
Related compounds: Alpha-Lipoic Acid, Benfotiamine, L-Glutathione, Betaine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery